A therapeutic comparison of ipratropium bromide and salbutamol in asthmatic patients.
A single-blind, crossover study was carried out in 43 asthmatic patients to compare the efficacy and tolerance of inhaled ipratropium bromide with inhaled salbutamol. One or other drug was given 3-times daily (0.04 mg ipratropium bromide or 0.2 mg salbutamol per dose) over a period of 4 weeks. Patients were then crossed over to the alternative medication for a further 4 weeks. The results of lung function tests performed at routine clinic visits and by the patients at home showed similar increases in peak flow and spirometry recordings, although more patients expressed a preference for salbutamol. Unwanted effects were minor with both drugs. It is suggested, therefore, that ipratropium bromide may be a useful alternative to beta-stimulants in some asthmatics.
D000328:Adult; D000368:Aged; D000420:Albuterol / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001286:Atropine Derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000009:adverse effects / Q000627:therapeutic use*; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010612:Pharyngitis / Q000139:chemically induced
D001286:Atropine Derivatives; D009241:Ipratropium; D000420:Albuterol